Stock events for Integra LifeSciences Holdings Corp. (IART)
Integra LifeSciences' stock has experienced significant volatility over the past six months, with a 52-week high of $24.37 and a 52-week low of $9.37. The stock dropped 10.5% following a second-quarter earnings report due to revenue decline and negative free cash flow. In February 2026, the company faced scrutiny after a Reuters Special Report highlighted concerns regarding its TruDi Navigation System. Ongoing operational and execution challenges, including supply disruptions, product recalls, and compliance issues, have led to underperformance of shares and repeated guidance cuts.
Demand Seasonality affecting Integra LifeSciences Holdings Corp.’s stock price
Integra LifeSciences' products and services exhibit some demand seasonality, with the company noting "normal seasonality" in its business. The fourth quarter may typically experience stronger demand, as seen with a sequential increase in revenue from the third quarter to the fourth quarter of 2025.
Overview of Integra LifeSciences Holdings Corp.’s business
Integra LifeSciences Holdings Corporation is a global medical technology company based in Princeton, New Jersey, operating in the Healthcare sector and Medical Devices industry. The company develops, manufactures, and markets specialized surgical implants and medical instruments, structured into two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment focuses on technologies for neurosurgery, neurocritical care, and otolaryngology, while the TT segment concentrates on complex wound surgery, surgical reconstruction, and peripheral nerve repair.
IART’s Geographic footprint
Integra LifeSciences Holdings Corp. has a global geographic footprint, serving hospitals, integrated health networks, and healthcare providers across the United States, Europe, Asia Pacific, and other international markets.
IART Corporate Image Assessment
Integra LifeSciences' brand reputation has been negatively affected by a voluntary global recall of certain products due to quality control failures and endotoxin testing deviations. A Reuters Special Report raised concerns about the TruDi Navigation System, potentially impacting the company's reputation concerning the safety and accuracy of its advanced medical technologies.
Ownership
Integra LifeSciences Holdings Corp. has a mixed ownership structure comprising institutional, retail, and individual investors. Institutional investors hold a significant portion of the company’s stock, with approximately 53.09% to 80.62% owned by them. Major institutional owners include BlackRock, Inc., Rubric Capital Management LP, and Vanguard Group Inc. Individual investors and insiders also hold shares, with insiders owning approximately 3.33% of the stock.
